Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lantus/Lixisenatide Combo Gets FDA Panel Nod, But Not Sanofi's Device

This article was originally published in The Pink Sheet Daily

Executive Summary

Pen for iGlarLixi should be redesigned to reduce risk of confusion and medication errors, advisory committee members say.

Advertisement

Related Content

Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles
Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS079452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel